REACH may cost six times more than previously estimated

September 4, 2009
Stephanie Sutton

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Implementing REACH, the European chemical legislation, will require a massive increase in animal testing and may cost six times more than previously estimated.

Implementing REACH, the European chemical legislation, will require a massive increase in animal testing and cost six times more than previously estimated. The findings come from an analysis conducted by researchers at the John Hopkins Bloomberg School of Public Health (MD, USA).

Speaking to Pharmaceutical Technology Europe (PTE), Thomas Hartung explained: "REACH expected that 27000 companies would submit 180000 preregistrations on 30000 chemicals. The big surprise, however, was that at the end of December 2008, 65000 companies had submitted 2.7 million preregistrations on 143000 chemicals." Hartung is Doerenkamp-Zbinden Professor and Chair for Evidence-based toxicology and Director of the Center for Alternatives to Animal Testing at the Bloomberg School of Public Health. He also co-chaired the 7th World Congress on Alternatives & Animal Use held in Rome (Italy) earlier this week.

In a press statement, Hartung described REACH as the "biggest investment ever into consumer safety".

However, he also believes that the scale of the challenge may have been underestimated; REACH could require 54 million research animals and 9.5 billion euro over the next 10 years. Approximately 90% of the projected animal use and 70% of the projected cost would come from research into reproductive toxicity testing. Usually, data must be collected from two generations of two species of animals.

Hartung explained to PTE that the second species is rarely used when testing chemicals because few new chemicals are produced at quantities high enough to trigger testing. "This is now different with REACH where the high-production chemicals are tested; so while only 70 two-generation studies were conducted over 25 years for industrial chemicals in the EU, we calculated 14000 for REACH if the guidance to industry is followed," he said.

He also added that: "European regulators need to understand that this is not only about animal numbers, but mainly about feasibility. It is not possible to create the test facilities. We do not have the toxicologists — a two-generation study assesses 80 endpoints including complex histopathology. Our analysis should not be misread as a pure ethical or financial concern — it is about a bottleneck identified for a programme we want to happen."

So what are the alternatives? Hartung suggested testing only suspicious chemicals. "Currently, the main trigger is production volume; at least prioritize the suspicious substances and leave the others for later when high-throughput strategies are developed," he said. He also offered further options including using an extended one-generation study and using in vitro approaches; according to Hartung, 80–90% of the classifications of chemicals in two-generation studies is based on testing toxicity for which promising tests do exist.

"We hope that our study helps to gain momentum for a revision of current practices in regulatory toxicology," Hartung told PTE. He also explained that Europe could benefit from a development similar to the US EPA toxicity testing strategy, which came into force in March 2009.

www.jhsph.edu